Targeting specific pathways or treating prostate cancer effectively

June 14, 2016 Source: Bio Valley

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Recently, a research paper entitled "Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy" published in the international journal Clinical Cancer Drugs revealed that researchers from the University of Abruzzo, Italy revealed Relevant experimental and clinical data on pharmacological inhibition of the PI3K/AKT/mTOR pathway in the body of prostate cancer patients.

The PI3K/AKT/mTOR pathway regulates cancer cell proliferation, tumor growth and survival through phosphorylation of different downstream molecules; prostate cancer tumor growth is often negatively regulated by phosphatase and tensin (PTEN), while phosphatase And tensin proteins are often inherited in a state of tumor formation.

In the article, the researchers elucidated the functional properties of different compounds inhibiting the activity of PI3K (phosphatidylinositol 3-kinase), AKT and mTOR, and they also analyzed the use of these inhibitory compounds alone and in combination with standardized therapy for malignant castration-resistant prostate cancer. The effect of (aggressive castration resistant prostate cancers, CRPC); CRPC is a characteristic stage of prostate cancer, and many patients often have cancerous bone metastases.

Current treatments for malignant castration-resistant prostate cancer require a variety of methods, such as medical therapy, surgery, and radiation therapy, but these treatments can only alleviate the progression of the disease; usually, researchers will find it in patients. The pharmacological tolerance of the patient; while the activation of the PI3K/AKT/mTOR pathway plays an important role in the patient's treatment, and blocking this pathway is important for increasing the effectiveness of standard therapies.

The final investigator, Festuccia, said that a number of preclinical data support the use of inhibitors of the PI3K/AKT/mTOR pathway in clinical trials of CRPC, which is currently used to treat a variety of other solid tumors. .

Calcium Alginate Dressing

Calcium Alginate Dressing,Calcium Alginate Silver Dressing,Seaweed Dressing For Wounds,Calcium Sodium Alginate

Roosin Medical Co.,Ltd , https://www.roosinmedical.com